Trigen adds at both ends

Trigen Ltd.’s acquisition of ProCorde GmbH in a stock deal, which was to be announced this week, will allow it to integrate upstream while adding a set of preclinical compounds in the same cardiovascular space.

"We wanted to move upstream and were looking for a company targeting synergistic markets," said Sanjay Kakkar, CEO of Trigen

Read the full 548 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE